Tuesday, July 16, 2013 9:32:47 AM
About Arestvyr(TM)
Arestvyr (Tecovirimat) is one of the first novel drugs to be developed, procured and now delivered to the Strategic National Stockpile under the post-9/11 legislative authority known as Project BioShield. Developed to serve as a therapeutic drug for treatment of smallpox, whether resulting from a terrorist attack, biowarfare or a new natural outbreak, Arestvyr is an investigational new drug not yet approved or licensed as safe and effective by the U.S. Food and Drug Administration (FDA). Arestvyr was known formerly as ST-246(R).
About SIGA Technologies, Inc.
In the United States and around the globe, populations face a serious but unmet need for new drugs to protect against potentially catastrophic emerging viral pathogens and biological weapons of mass destruction. We are a pharmaceutical company specializing in discovering and developing pharmaceutical solutions for some of the most lethal pathogens — smallpox, Ebola, dengue, Lassa fever and other dangerous viruses. Our objective is to discover, develop, and commercialize drugs to prevent and treat these high-priority threats. Our mission is to disarm dreaded viral diseases and create robust, modern biodefense countermeasures. For more information about SIGA, please visit SIGA's web site at www.siga.com.
Forward-Looking Statements
This press release contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements relating to performance of both parties under SIGA's contract with the Biomedical Advanced Research and Development Authority (BARDA), SIGA's efforts to seek approval and licensing from the United States Food and Drug Administration, and SIGA's capabilities in antiviral drug discovery and development. Forward-looking statements are based on management's estimates, assumptions and projections, and are subject to uncertainties, many of which are beyond our control. Actual results may differ materially from those anticipated in any forward-looking statement. Factors that may cause such differences include (i) the risk that potential products that appear promising to us or our collaborators cannot be shown to be efficacious or safe in subsequent animal, pre-clinical or clinical trials, (ii) the risk that we or our collaborators will not obtain appropriate or necessary governmental approvals to market these or other potential products, (iii) the risk that we may not be able to obtain anticipated funding for our development projects or other needed funding, (iv) the risk that we may not complete performance under the BARDA contract on schedule or in accordance with the contractual terms, (v) the risk that we may not be able to secure or enforce sufficient legal rights in our products, including intellectual property protection, (vi) the risk that any challenge to our patent and other property rights, if adversely determined, could affect our business and, even if determined favorably, could be costly, (vii) the risk that regulatory requirements applicable to our products may result in the need for further or additional testing or documentation that will delay or prevent seeking or obtaining needed approvals to market these products, (viii) the risk that one or more protests could be filed and upheld in whole or in part or other governmental action taken, in either case leading to a delay of performance under our contract with BARDA, or other governmental contracts, (ix) the risk that our BARDA contract is modified or canceled at the request or requirement of the U.S. Government, (x) the risk that the volatile and competitive nature of the biotechnology industry may hamper our efforts to develop or market our products, (xi) the risk that changes in domestic and foreign economic and market conditions may affect our ability to advance our research or products adversely, (xii) the effect of federal, state or foreign regulation, including drug regulation and international trade regulation, on our business, (xiii) the risk that our outstanding indebtedness may make it more difficult to obtain additional financing, (xiv) the risk that the U.S. Government's responses (including inaction) to the national and global economic situation, including possible courses of action related to the so-called "sequester," may affect our business adversely, (xv) the risk that our internal controls will not be effective in detecting or preventing a misstatement in our financial statements, (xvi) the risk that some amounts received and recorded as deferred revenue ultimately may not be recognized as revenue, (xvii) the risk that the recent remand to the Delaware Chancery Court could result in a burdensome new award of damages, (xviii) the risk that that remand may result in extended and expensive litigation, (xix) the risk that our litigation with PharmAthene may impede our efforts to continue to grow our company, and (xx) the risk that we may not be able to establish our intended positions or otherwise not prevail in any further court proceedings. More detailed information about our company and risk factors that may affect the realization of forward-looking statements, including the forward-looking statements set forth here, is set forth in our filings with the Securities and Exchange Commission (the SEC), including our Annual Report on Form 10-K for the fiscal year ended December 31, 2012, as amended by SIGA's 10-K/A as filed on May 15, 2013, and in other documents that we have filed with the SEC. We urge investors and security holders to read those documents free of charge at the SEC's website at http://www.sec.gov. Interested parties may also obtain those documents free of charge directly from us. Forward-looking statements speak only as of the date they are made, and except for our ongoing obligations under the federal securities laws, we undertake no obligation to update publicly any forward-looking statement whether as a result of new information, future events or otherwise.
.
.
Contact:.
.
KCSA Strategic Communications
Todd Fromer / Rob Fink
212-896-1215 / 1206
Tfromer@kcsa.com / rfink@kcsa.com
Recent SIGA News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2024 08:58:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 08:06:24 PM
- SIGA Reports Financial Results for Three Months Ended March 31, 2024 • GlobeNewswire Inc. • 05/07/2024 08:05:00 PM
- SIGA Technologies to Host Business Update Call on May 7 Following Release of First-Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/01/2024 09:00:00 PM
- SIGA Amends International Promotion Agreement with Meridian to Enhance International Growth Opportunities of Oral TPOXX® • GlobeNewswire Inc. • 04/01/2024 08:05:00 PM
- SIGA Names Larry Miller General Counsel • GlobeNewswire Inc. • 03/25/2024 11:30:00 AM
- SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2023 • GlobeNewswire Inc. • 03/12/2024 08:05:00 PM
- SIGA Declares Special Cash Dividend of $0.60 Per Share • GlobeNewswire Inc. • 03/12/2024 11:30:00 AM
- SIGA Technologies to Host Business Update Call on March 12th, 2024 Following Release of Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 03/05/2024 12:30:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/01/2024 08:54:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/30/2024 10:04:04 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 01/30/2024 10:01:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 09:01:28 PM
- SIGA Announces Appointment of Diem Nguyen, Ph.D., MBA, as New Chief Executive Officer • GlobeNewswire Inc. • 01/22/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2024 01:49:12 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/07/2023 10:00:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/07/2023 09:05:39 PM
- SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2023 • GlobeNewswire Inc. • 11/07/2023 09:05:00 PM
- SIGA Technologies to Host Business Update Call on November 7th, 2023 Following Release of Third Quarter 2023 Financial Results • GlobeNewswire Inc. • 10/26/2023 11:30:00 AM
- SIGA Announces Creation of Joint Procurement Mechanism by European Commission with Anticipated Initial Orders of Approximately $18 Million for Oral TPOXX® (Tecovirimat) by Participating Countries • GlobeNewswire Inc. • 10/23/2023 12:00:00 PM
- SIGA Technologies Names Dr. Jay K. Varma as EVP and Chief Medical Officer • GlobeNewswire Inc. • 09/06/2023 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/06/2023 10:05:19 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2023 08:50:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2023 08:05:20 PM
- SIGA Reports Financial Results for Three and Six Months Ended June 30, 2023 • GlobeNewswire Inc. • 08/08/2023 08:05:00 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM